In 2021, 16 million US adults reported lifetime amphetamine misuse, and that same year 1.3 million people had an amphetamine use disorder. Even the biology is sharply dose and duration dependent, with chronic high dose use linked to 20 to 30 percent dopamine transporter downregulation, while overdose can drive hyperthermia up to 42°C. The figures also swing from medical use in ADHD and narcolepsy to major public health risks like 2 to 4 fold higher stroke rates and penalties that can reach 40 years in federal prison.
Key Takeaways
- Chronic high-dose amphetamine use causes dopamine transporter downregulation by 20-30%.
- Amphetamine overdose can cause hyperthermia up to 42°C.
- Cardiovascular risks include tachycardia; HR increases 20-50 bpm.
- In 2021, 16 million US adults reported lifetime amphetamine misuse.
- Past-year amphetamine use disorder affected 1.3 million US people in 2021.
- Among US high school seniors, 3.9% used amphetamines nonmedically in 2022.
- Amphetamine is Schedule II under US Controlled Substances Act.
- Amphetamine possession illegal without prescription in most countries.
- DEA production quotas for amphetamine: 25,000 kg in 2023.
- Amphetamine is used to treat ADHD in children over 3 years old.
- Adderall (mixed amphetamine salts) is approved for narcolepsy.
- Dextroamphetamine (Dexedrine) treats ADHD at doses 5-40 mg/day.
- Amphetamine was first synthesized in 1887 by Romanian chemist Lazăr Edeleanu.
- The chemical formula of amphetamine is C9H13N.
- Amphetamine has a molecular weight of 135.21 g/mol.
High dose amphetamine can downregulate dopamine transporters and raise dangerous risks, yet it is also used medically for ADHD.
Related reading
01 · Category
Adverse Effects29 stats
01
Chronic high-dose amphetamine use causes dopamine transporter downregulation by 20-30%.
02
Amphetamine overdose can cause hyperthermia up to 42°C.
03
Cardiovascular risks include tachycardia; HR increases 20-50 bpm.
04
Amphetamines associated with 2-4 fold increased stroke risk.
05
Psychosis incidence in chronic users: 20-40%.
06
Amphetamine withdrawal features depression in 60-80% of users.
07
Long-term use leads to dental decay ("meth mouth") in 30-50% of heavy users.
08
Amphetamines increase myocardial infarction risk by 3-fold acutely.
09
Neurotoxicity: amphetamine reduces striatal dopamine by 20-50% in primates.
10
Anxiety disorders in 25% of amphetamine-dependent individuals.
11
Skin picking and ulceration common; 40% of chronic users affected.
12
Amphetamine-induced cardiomyopathy in 10-15% of heavy users.
13
Cognitive deficits persist 1 year post-abstinence in 30% of users.
14
Hepatotoxicity risk elevated 2-fold with chronic use.
15
Amphetamines linked to rhabdomyolysis in overdose cases (5-10%).
16
Insomnia duration averages 3-5 days in binge use.
17
Amphetamines cause serotonin syndrome risk with SSRIs (rare, <1%).
18
Chronic use associated with Parkinson's-like symptoms in 10%.
19
Appetite suppression leads to 10-20% body weight loss in 6 months.
20
Psychotic symptoms resolve in 80% within 1 week abstinence.
21
Amphetamine elevates blood pressure by 10-20 mmHg systolic.
22
Seizure risk 2-5% in overdose.
23
Memory impairment: 15-25% deficit in chronic users.
24
Amphetamine vasoconstriction causes peripheral ischemia.
25
Renal failure in 5% of severe overdoses.
26
Aggression and violence 3-fold increased in users.
27
Amphetamine tolerance develops within weeks to dopamine effects.
28
Pulmonary hypertension risk with IV use (rare).
29
Sexual dysfunction: priapism in males (0.1-1%).
Interpretation
Adverse Effects Interpretation
From an adverse effects perspective, chronic high dose use can downregulate dopamine transporters by 20 to 30% and drive serious neuropsychiatric harm, with psychosis occurring in 20 to 40% of chronic users while stroke risk rises 2 to 4 fold.
02 · Category
Epidemiology/prevalence28 stats
01
In 2021, 16 million US adults reported lifetime amphetamine misuse.
02
Past-year amphetamine use disorder affected 1.3 million US people in 2021.
03
Among US high school seniors, 3.9% used amphetamines nonmedically in 2022.
04
Lifetime prevalence of amphetamine use in US college students is 11.5%.
05
In Australia, 7.2% of population aged 14+ used amphetamines lifetime in 2019.
06
US emergency department visits for amphetamines rose 103% from 2011-2019.
07
2.7% of US 12th graders reported past-year Adderall misuse in 2022.
08
Global amphetamine-type stimulant seizures reached 200 tons in 2020.
09
In Europe, 1.3% of adults used amphetamines in past year (2022).
10
US prescription stimulant misuse among adults 18-25: 6.2% past year (2021).
11
Amphetamine use disorder prevalence in US military veterans: 5-10%.
12
Past-month nonmedical amphetamine use in US: 0.2% overall population (2021).
13
In Canada, 1.5% of students grade 7-12 used amphetamines nonmedically (2019).
14
Amphetamine overdose deaths in US: 3,452 in 2021.
15
75% of amphetamine users report polysubstance use.
16
In US, ADHD medication diversion rate: 16% of prescriptions.
17
Amphetamines in 25% of US ADHD treatment prescriptions.
18
Past-year misuse among US young adults 18-25: 10.1% (2021 NSDUH).
19
Amphetamine-related hospitalizations in US: 110,000 annually pre-COVID.
20
In New Zealand, 2.5% lifetime amphetamine use (2019).
21
50% of US college students obtain stimulants illicitly for studying.
22
Amphetamine use among US homeless: 15-20%.
23
Global ATS users: 36 million (2022 UNODC).
24
In Sweden, amphetamine most common illicit stimulant (1.2% past year).
25
US 8th graders nonmedical amphetamine use: 1.5% (2022).
26
Female amphetamine use rising faster than males in US (20% increase).
27
Amphetamine positive urine tests in workplace: 0.5% (2022).
28
Amphetamine cessation rates with behavioral therapy: 20-30% at 1 year.
Interpretation
Epidemiology/prevalence Interpretation
Across these epidemiology and prevalence snapshots, amphetamine misuse and related harms appear widespread and increasing, with 16 million US adults reporting lifetime misuse in 2021 and US emergency department visits for amphetamines jumping 103 percent from 2011 to 2019.
03 · Category
Legal/regulation23 stats
01
Amphetamine is Schedule II under US Controlled Substances Act.
02
Amphetamine possession illegal without prescription in most countries.
03
DEA production quotas for amphetamine: 25,000 kg in 2023.
04
Amphetamine trafficking penalties: up to 40 years US federal prison.
05
In UK, amphetamine is Class B drug; max 14 years possession.
06
Amphetamine precursors like phenylacetone regulated under UN conventions.
07
FDA requires REMS for amphetamine ADHD products due to abuse potential.
08
Amphetamine prescription limited to 30-day supply in some US states.
09
In Australia, amphetamine Schedule 8 (controlled drug).
10
Canada classifies amphetamine as Schedule I narcotic.
11
Amphetamine analoges like MDMA also scheduled internationally.
12
US state laws vary; some require database checks for amphetamine Rx.
13
Global amphetamine production estimated 500 tons illicit annually.
14
Amphetamine prescription fraud cases: 5,000 annually US.
15
EU Early Warning System monitors 50+ amphetamine NPS.
16
Amphetamine manufacturing labs seized: 1,200 in US 2022.
17
In Japan, amphetamine (shabu) is strictly prohibited; death penalty possible.
18
Prescription amphetamine sales US: $5 billion in 2022.
19
UN 1988 Convention schedules amphetamine precursors.
20
Amphetamine theft from pharmacies: 500 incidents/year US.
21
In Mexico, amphetamine production fuels 20% of cartel revenue.
22
US amphetamine import quotas tightly controlled by DEA.
23
Amphetamine analog scheduling under US Analog Act.
Interpretation
Legal/regulation Interpretation
For the legal and regulation angle, amphetamine is tightly controlled worldwide, with the US DEA setting a 25,000 kg production quota in 2023 and the UK classing it as Class B with up to 14 years for possession, alongside severe trafficking penalties of as much as 40 years in federal prison.
More related reading
04 · Category
Medical Uses21 stats
01
Amphetamine is used to treat ADHD in children over 3 years old.
02
Adderall (mixed amphetamine salts) is approved for narcolepsy.
03
Dextroamphetamine (Dexedrine) treats ADHD at doses 5-40 mg/day.
04
Amphetamines improve attention and reduce hyperactivity in 70-80% of ADHD patients.
05
Lisdexamfetamine (Vyvanse) is a prodrug of dextroamphetamine for ADHD.
06
Amphetamine doses for obesity treatment were historically 5-30 mg/day.
07
Evekeo (amphetamine sulfate) approved for ADHD and exogenous obesity.
08
Amphetamines increase wakefulness in narcolepsy patients by 4-6 hours.
09
In treatment-resistant depression, amphetamines show 50% response rate adjunctively.
10
Amphetamine promotes weight loss of 0.5-1 kg/week in short-term obesity therapy.
11
Mydayis (extended-release amphetamines) for ADHD in ages 13+ up to 50 mg/day.
12
Amphetamines used off-label for treatment-emergent sexual dysfunction in SSRI users.
13
Amphetamine used in veterinary medicine for lethargy.
14
Amphetamines effective in 75% of narcolepsy cataplexy cases adjunctively.
15
Zenzedi (dextroamphetamine) for ADHD starting 2.5 mg.
16
ProCentra (liquid dextroamphetamine) for ADHD ages 6+.
17
Amphetamine reduces fatigue in multiple sclerosis patients (off-label).
18
In Parkinson's, amphetamines improve bradykinesia temporarily.
19
Historical use for asthma; bronchodilation via beta-2 agonism.
20
Amphetamine paste used in some dental applications historically.
21
Adzenys XR-ODT (amphetamine) for ADHD ages 6+.
Interpretation
Medical Uses Interpretation
In medical uses, amphetamine therapies stand out for improving ADHD outcomes in about 70 to 80% of patients, spanning children over age 3 with options like dextroamphetamine 5 to 40 mg per day and lisdexamfetamine as a prodrug of dextroamphetamine, while also extending to conditions such as narcolepsy with Adderall.
05 · Category
Pharmacology26 stats
01
Amphetamine was first synthesized in 1887 by Romanian chemist Lazăr Edeleanu.
02
The chemical formula of amphetamine is C9H13N.
03
Amphetamine has a molecular weight of 135.21 g/mol.
04
Amphetamine is a chiral molecule with dextroamphetamine being the more potent enantiomer.
05
Amphetamine acts primarily by releasing monoamines like dopamine, norepinephrine, and serotonin.
06
Oral bioavailability of amphetamine is approximately 70-90%.
07
Half-life of amphetamine in adults is 9-11 hours.
08
Amphetamine increases synaptic dopamine by inhibiting reuptake and promoting release.
09
Peak plasma concentration of amphetamine occurs 3 hours after oral dose.
10
Amphetamine pKa is 9.9, making it a weak base.
11
Dextroamphetamine has 3-5 times the potency of levoamphetamine on CNS.
12
Amphetamine is metabolized primarily by CYP2D6 in the liver.
13
Volume of distribution for amphetamine is 3-4 L/kg.
14
Amphetamine crosses the blood-brain barrier rapidly due to lipophilicity.
15
Therapeutic plasma levels of amphetamine range 20-50 ng/mL.
16
Amphetamine sulfate is the most common pharmaceutical form.
17
LogP (octanol-water partition coefficient) of amphetamine is 1.76.
18
Amphetamine melting point is 102-104°C.
19
Amphetamine is excreted 30-40% unchanged in urine.
20
Urinary pH affects amphetamine excretion; acidic urine increases elimination.
21
Amphetamine was used in WWII by militaries for alertness.
22
Amphetamine elevates extracellular dopamine by 1000% at high doses.
23
Norepinephrine release by amphetamine is 10-fold baseline.
24
Amphetamine VMAT2 inhibition leads to cytoplasmic monoamine accumulation.
25
Levoamphetamine contributes more to peripheral effects.
26
Protein binding of amphetamine is <20%.
Interpretation
Pharmacology Interpretation
From a pharmacology perspective, amphetamine shows strong oral exposure with an estimated 70 to 90% bioavailability and this matches its mechanism of releasing monoamines such as dopamine and norepinephrine, helping explain why the more potent dextroamphetamine enantiomer can have a pronounced biological effect.
report visual · Comparison
Amphetamine-related impact has risen over time
US emergency department visits for amphetamines increased substantially from 2011 to 2019.
US emergency department visits for amphetamines rose 103% from 2011-2019.103%
Amphetamine overdose can cause hyperthermia up to 42°C.
42
Chronic high-dose amphetamine use causes dopamine transporter downregulation by 20-30%.
-30%
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Amphetamine Statistics. Gitnux. https://gitnux.org/amphetamine-statistics
MLA
Timothy Grant. "Amphetamine Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/amphetamine-statistics.
Chicago
Timothy Grant. 2026. "Amphetamine Statistics." Gitnux. https://gitnux.org/amphetamine-statistics.
Sources & references
25 datasets cited across this report · attribution is report-level